ASXL1 and thrombocytosis disease: Interestingly, with the notable differences of thrombocytosis and a lower median age, our patients share with CHIP individuals an unremarkable clinical history, with a very indolent disease, and variants affecting genes regarded as initiator of clonal expansion (e.g., TET2 or ASXL1), as well as genes with higher impact on disease progression (e.g., RUNX1).